Whitehawk Therapeutics, Inc. Common Stock (WHWK) is a publicly traded Healthcare sector company. As of May 21, 2026, WHWK trades at $4.17 with a market cap of $210.17M and a P/E ratio of -12.68. WHWK moved +4.18% today. Year to date, WHWK is +66.80%; over the trailing twelve months it is +112.06%. Its 52-week range spans $1.39 to $5.50. Analyst consensus is buy with an average price target of $7.33. Rallies surfaces WHWK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Whitehawk Therapeutics Raises $87.5M in Private Placement to Fund ADC Pipeline: Whitehawk Therapeutics has secured $87.5 million through a PIPE financing by selling 4.33 million common shares at $3.92 each and pre-funded warrants for 17.99 million shares at $3.9199. The net proceeds will fund ADC pipeline development and extend its cash runway into H2 2028.
| Metric | Value |
|---|---|
| Price | $4.17 |
| Market Cap | $210.17M |
| P/E Ratio | -12.68 |
| EPS | $-0.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.50 |
| 52-Week Low | $1.39 |
| Volume | 17 |
| Avg Volume | 0 |
| Revenue (TTM) | $7.14M |
| Net Income | $-20.60M |
| Gross Margin | 89.36% |
5 analysts cover WHWK: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.33.